OGN · Organon & Co.
$13.76
+0.00 (+0.00%)
At close · Aug 28
Going-concern doubt
— cleared Jul 31, 2026
The latest filing no longer states the doubt (first flagged May 4, 2026).
View the 10-Q filed Jul 31, 2026Market Cap
$3.61B
Shares
262.61M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$13.76
Open$13.76
Day$13.76–13.77
52W close$5.70–13.77
Avg vol 30d2.8M
Short int15.1M · 5.8% float · 6.1d
Short vol75%
Last earningsApr 30, 2026
DataMay 2021–Aug 2026
Filing10-Q · Jul 31
Up next
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Jul 31, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
High
Market backdrop
VIX 14.4 · calm
Equity put/call 0.62
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+36%
above
Price vs 50-day avg
+1%
above
RSI (14)
73
overbought
MACD trend
Negative
52-week position
100%
near high
Momentum
relative strength
1-month return
+2%
trailing
6-month return
+111%
trailing
YTD return
+92%
this year
Relative strength
+97%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $14 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +124 funds added
Insider flow
Distributing
Net -$200.3K over 90 days · 100% sells
Short interest
Falling
5.76% of float · ▼ -9.9% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
640 holders — mid 3-yr range
Squeeze score
63
elevated · 0–100
Fundamentals
Revenue growth
−3%
Y/Y
Gross margin
53%
contracting
EPS growth
−78%
Y/Y
Free cash flow
$538.0M
Valuation
P/E 17.6
below peers
Balance sheet
$8.1B
net debt
Quant / Vol
risk profile
Volatility
67%
annualized · 1-yr
Max drawdown
−48%
past year
ATR
0.3%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed Feb 12, 2026
Full Year 2026
Revenue
$6.2B
Adjusted EBITDA
Non-GAAP
$1.9B
Effective non-GAAP tax rate
Non-GAAP
27.5% – 29.5%
Depreciation
Non-GAAP
$140M
Interest
Non-GAAP
$500M
FY 2026
Revenue
Non-GAAP
$6.2B
Interest
$500M
Depreciation
$140M
Prior guidance
period ended
· from the 8-K filed Nov 10, 2025
Revenue
· Full year 2025
$6.2B – $6.25B
FX translation impact
· Full year 2025
$35M – $45M
Adjusted EBITDA margin (Non-GAAP)
· Full year 2025
31%
Interest
· Full year 2025
$510M
Depreciation
· Full year 2025
$135M
Free Cash Flow before one-time costs
· full-year 2025
at least $900M
Interest
· Full-year 2025
$510M
Depreciation
· Full-year 2025
$135M
Guided vs delivered
· last 4 settled
Revenue
Full year 2025
guided $6.2B – $6.25B
$6.22B
In line
Revenues
Full Year 2024
guided $6.38B – $6.43B
$6.4B
In line
Revenue
full year 2023
guided $6.15B – $6.25B
$6.26B
Beat +1.0%
Revenue
full year 2022
guided $6.1B – $6.2B
$6.17B
In line
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+36%
Bullish
Price vs 50-day avg
+1%
Bullish
RSI (14)
73
Bearish
MACD trend
Negative
Bearish
52-week position
100%
Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross)
No cross
50d $14 › 200d $10 — 50d above 200d
Institutional flow
Accumulating
+4% holders QoQ · +124 funds added
Insider flow
Distributing
Net -$200.3K over 90 days · 100% sells
Short interest
Falling
5.76% of float · ▼ -9.9% MoM · 6.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
640 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $6
Now $14 · 100%
Range high $14
vs 200-day avg +36%
vs 50-day avg +1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA margin (Non-GAAP) non-GAAP | 28.4% | Q1 2026 | — |
|
|
|||
| Adjusted Non-GAAP Gross Margin non-GAAP | 59% | Three Months Ended March 31, 2026 | — |
|
|
|||
| Adjusted Non-GAAP Gross Profit non-GAAP | $861M | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Gross Profit $783M
+$21M Manufacturing network costs
+$3M Stock-based compensation
+$47M Amortization
+$7M Acquisition-related costs
+$0M Other
= Adjusted Non-GAAP Gross Profit $861M
|
|||
| Adjusted Non-GAAP Research and development expenses non-GAAP | $86M | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Research and development expenses $93M
-$3M Manufacturing network costs
-$3M Stock-based compensation
-$1M Other
= Adjusted Non-GAAP Research and development expenses $86M
|
|||
| Adjusted Non-GAAP Selling, general and administrative expenses non-GAAP | $398M | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Selling, general and administrative expenses $424M
-$13M Stock-based compensation
+$0M Restructuring related charges
-$13M Other
= Adjusted Non-GAAP Selling, general and administrative expenses $398M
|
|||
| EBITDA (Non-GAAP) non-GAAP | $409M | Three Months Ended March 31, 2026 | — |
|
|
|||
| Non-GAAP Adjusted Diluted Earnings per Share non-GAAP | $0.71 | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Diluted Earnings per Share $0.55
+$0.16 Total impact of Non-GAAP adjustments
= Non-GAAP Adjusted Diluted Earnings per Share $0.71
|
|||
| Non-GAAP Adjusted EBITDA non-GAAP | $415M | Q1 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Reported Net Income $146M
+$38M Depreciation
+$47M Amortization
+$111M Interest expense
+$67M Income tax expense (benefit)
+$31M Restructuring and related charges
+$27M Manufacturing network related
+$7M Acquisition-related costs
-$5M Change in contingent consideration
-$81M Jada divestiture
+$8M Other costs
+$19M Stock-based compensation
= Adjusted EBITDA (Non-GAAP) $415M
|
|||
| Non-GAAP Adjusted Net Income non-GAAP | $188M | Three Months Ended March 31, 2026 | — |
|
|
|||
GAAP → non-GAAP reconciliationGAAP GAAP Reported Net Income $146M
+$78M Cost of sales adjustments
+$26M Selling, general and administrative adjustments
+$7M Research and development adjustments
-$81M Jada divestiture
+$31M Restructuring
-$5M Change in fair value of contingent consideration
-$3M Other (gain) expense, net
-$11M Tax impact on adjustments above
= Non-GAAP Adjusted Net Income $188M
|
|||
| Adjusted net income non-GAAP | $954M | Full Year 2025 | — |
| Free Cash Flow non-GAAP | $659M | Full Year 2025 | — |
| Free Cash Flow Before One-Time Costs non-GAAP | $960M | Full Year 2025 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - General — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
OGN
this stock
Organon & Co.
|
$3.61B | +91.9% | -2.9% | 17.6 | 5.8% |
|
LLY
ELI LILLY & Co
|
$1.11T | +9.3% | +44.7% | 39.5 | 0.7% |
|
JNJ
Johnson & Johnson
|
$645.95B | +29.5% | +6.0% | 31.1 | 0.9% |
|
ABBV
AbbVie Inc.
|
$451.46B | +11.8% | +8.6% | 72.2 | 1.0% |
|
MRK
Merck & Co., Inc.
|
$368.94B | +40.9% | +1.3% | 119.6 | 1.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| OGN | +0.1% | +1.6% | +110.7% | +1.6% | +91.9% |
| SPY | +0.5% | +3.0% | +13.4% | +3.0% | +12.8% |
| vs SPY | -0.4% | -1.4% | +97.3% | -1.4% | +79.1% |
Capital returns
Latest dividend
$0.02
/ share · ex Aug 14, 2026
Paid (TTM)
$0.08
/ share · 4 payouts
Dividend yield (TTM, derived)
0.58%
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
Key facts
CIK
1821825
CUSIP
68622V106
13F (30d)
444 filings
424 filers
Visit website
Investor relations